Navigation Links
XELR8 Holdings Announces Record First Quarter Revenue

- Management to Host Conference Call Today at 11:30 a.m. ET -

DENVER, May 1 /PRNewswire-FirstCall/ -- XELR8 Holdings, Inc. (Amex: BZI), a provider of liquid nutritional, functional foods, beverages and nutritional supplements, today announced its financial results for three months ended March 31, 2008.

Financial and operational highlights for First Quarter of Fiscal 2008:

-- Revenue increased 138% over prior year period to $1.6 million

-- Gross profit was $1.2 million, an improvement of $0.6 million from one

year ago

-- Cash and cash equivalents were $2.5 million as of March 31, 2008

Total revenue for the first quarter ended March 31, 2008 was $1.6 million, an 82% increase compared to total revenue of $0.9 million for the fiscal year ended March 31, 2007. Gross profit grew to $1.2 million for the three months ended March 31, 2008, up 115% from $0.6 million in the prior year period. Gross margin in the quarter was 77%, an improvement of 12%, from 65% same quarter one year ago, due to increased sales of Bazi, which carries a higher gross margin compared to the legacy products. Net loss for the three months ended March 31, 2008, decreased 43% to $0.75 million, or $(0.05) per share, compared to a loss of $1.4 million, or $(0.13) per share, in the prior year.

The Company's balance sheet continues to remain strong. As of March 31, 2008, cash and cash equivalents were approximately $2.5 million, which includes the proceeds from the $0.5 million financing completed during the quarter. Total shareholders' equity at the three months ended March 31, 2008 was $2.2 million and the Company remains debt free.

Mr. John Pougnet, Chief Executive Officer of XELR8, commented, "I am pleased to report another record revenue quarter. Bazi continues to gain traction in the marketplace and showed major improvements partially due to our successful gathering of distributors in February at our national event as well as new sales aids and incentives offered. In the first quarter sales of Bazi rose approximately 138% from same period one year ago, to $1.4 million, or an increase of $0.8 million. Bazi represented 89% of the Company's total sales in the quarter versus 68% last year as customers favor the convenience and simplicity Bazi offers them."

Mr. Pougnet continued, "The Company's main driver in the near-term is to continue to focus our efforts on growing sales of Bazi, which has shown tremendous growth in the last year, when it was first launched. As of March 31, 2008, we had 9,044 participants nationwide marketing Bazi, which was a 7.5% increase since our last tally of 8,416 participants which was as of February 29, 2008, partially due to the successful distributor convention in Las Vegas. Since then, we continue to remain in close contact with our distributors to obtain constant feedback as well as assist them in building their business as well. Recently we have offered new incentives and bonus features and conducted regional 'Go Diamond' events, in six major cities nationwide."

"Our operating plan for 2008 remains on target and is focused on the continued growth and market penetration of Bazi by increasing the number of independent distributors and customers, which will help drive revenues and improve gross profit. Our cash burn has been diminished and the visibility to produce positive cash flow is vivid and within reach in the coming quarters," concluded Mr. Pougnet.

Additionally, XELR8 and its liquid nutritional drink "Bazi" were featured on's video segment entitled "Direct Selling is So Money" on Wednesday, April 30th. In the segment XELR8 distributor Emma Stith was interviewed along with Sandy Greenberg, distributor advocate and XELR8 founder. You can view the segment by cutting and pasting this url into your browser: YAH OO&cm_cat=FREE&cm_ite=NA#10414473

There will be a conference call today at 11:30 a.m. ET with the investment community, featuring John Pougnet, Chief Executive Officer of XELR8 Holdings, Inc. Interested parties may participate in the call by dialing 877-407-8293; international callers dial 201-689-8349. In addition, the replay of the conference call will be available approximately two hours after the call has ended. The replay can be accessed at: and will be archived for 30 days.

About XELR8 Holdings, Inc.

XELR8 Holdings, Inc. is a provider of nutritional foods and beverages designed to help enhance physical health and overall performance. XELR8 has developed a comprehensive line of nutritional supplements and functional foods designed in systems that are easy to take, simple to understand, and conveniently fit within a lifestyle. These include the Company's Eat/Drink/Snack System; Peak Performance System; and its newest market entry, Bazi(TM), a powerful, concentrated, antioxidant (Vitamins A, C & E) nutritional drink packed with eight different super fruits and berries, including the Chinese jujube plus 12 vitamins and 68 minerals, providing all the daily vitamins and minerals you need in a single, convenient, one-ounce shot.

XELR8's commitment to quality, science and research has earned the Company a loyal following of over 350 world-class athletes and an elite list of endorsers, such as 3-time World Series Champion Curt Schilling, five-time Cy Young Award Winner Randy Johnson; Super Bowl Champions Mike Alstott and Lawyer Milloy; professional football star Cadillac Williams; Olympians Briana Scurry and Caroline Lalive; Stanley Cup Winner Blake Sloan; and PGA Tour Professional Tom Pernice, Jr. XELR8 products are only available through independent distributors located throughout the nation. For more information about XELR8, please visit or

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including prospects for XELR8's distribution network. Actual results may differ from those discussed in such forward-looking statements. These forward-looking statements include risks and uncertainties that include the Company's ability to attract and retain distributors; changes in demand for the Company's products; changes in the level of operating expenses; changes in general economic conditions that impact consumer behavior and spending; product supply; the availability, amount, and cost of capital for the Company; and the Company's use of such capital. More information about factors that potentially could affect the Company's financial results is included in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006 and all subsequent filings. Certain statements in this release regarding the Company's agreements are in accordance with the guidelines established by the Federal Trade Commission for endorsements in advertising.


Stephen D. Axelrod, CFA

John Pougnet, CEO Alisa Steinberg (Media)

XELR8 Holdings, Inc. Wolfe Axelrod Weinberger Assoc. LLC

(303) 316-8577 (212) 370-4500



For the Quarters Ended

March 31 December 31

2008 2007


Current assets:

Cash and cash equivalents $2,469,361 $2,245,858

Accounts receivable, net of

allowance for doubtful accounts

of $14,079 and $12,231, respectively 1,220 7,460

Inventory, net of allowance for

obsolescence of $174,687 and $189,403,

respectively 290,823 370,843

Prepaid expenses and other current

assets 325,207 329,015

Total current assets 3,086,611 2,953,176

Intangible assets, net 17,652 17,959

Property and equipment, net 68,738 81,405

Total assets $3,173,001 $3,052,540


Current liabilities:

Accounts payable and accrued expenses $974,172 $832,697

Total Liabilities 974,172 832,697

Commitments and Contingencies


Preferred stock, authorized 5,000,000

shares, $.001 par value, none issued or

outstanding - -

Common stock, authorized 50,000,000

shares, $.001 par value, 15,697,170 and

15,197,170 shares issued and outstanding

respectively 15,697 15,197

Additional paid in capital 23,424,505 22,696,657

Accumulated (deficit) (21,241,373) (20,492,011)

Total shareholders' equity 2,198,829 2,219,843

Total liabilities and shareholders'

equity $3,173,001 $3,052,540



Three Months Ended March 31, 2008 and 2007

For the Three For the Three

Months Ended Months Ended

March 31, 2008 March 31, 2007

Net sales $1,577,784 $869,075

Cost of goods sold 359,578 305,593

Gross profit 1,218,206 563,482

Operating expenses:

Selling and marketing expenses 1,090,792 629,266

General and administrative expenses 868,886 849,521

Research and development expenses 424 614

Depreciation and amortization 11,844 11,779

Total operating expenses 1,971,946 1,491,180

Net (loss) from operations (753,740) (927,698)

Other income (expense)

Interest income 19,278 3,126

Other expense (13,770) -

(Loss) on disposal of asset (1,130)

Interest (expense) - (439,537)

Total other income (expense) 4,378 (436,411)

Net (loss) $(749,362) $(1,364,109)

Net (loss) per common share

Basic and diluted net (loss) per share $(0.05) $(0.13)

Weighted average common shares

outstanding, basic and diluted 15,334,533 10,753,350



Three Months Ended March 31, 2008 and 2007

2008 2007

Cash flows from operating activities:

Net income (loss) $(749,362) $(1,364,109)

Adjustments to reconcile

Depreciation and amortization 11,844 11,779

Stock and stock options issued

for services 275,375 474,912

Expense related to anti-dilution

of warrants 13,770 -

Loss on asset disposal 1,130 -

Interest expense and amortization

related to bridge loan financing - 428,889

Change in allowance for doubtful

accounts 1,848 2,368

Change in allowance for inventory

obsolescence (14,716) 81,450

Change in allowance for product

returns 10,092 30,866

Changes in assets and liabilities:

Accounts receivable 4,392 (4,052)

Inventory 94,736 (40,488)

Other current assets 3,808 79,511

Accounts payable and accrued

expenses 131,383 122,355

Net cash (used) by operating

activities (215,700) (176,519)

Cash flows from financing activities:

Proceeds from bridge loan financing - 250,000

Repayments of bridge financing - (500,000)

Issuance of common stock, net 439,203 1,806,404

Net cash provided by financing

activities 439,203 1,556,404



OF THE PERIOD 2,245,858 76,147


PERIOD $2,469,361 $1,456,032

SOURCE XELR8 Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. XELR8 Holdings Announces Fiscal 2007 Financial Results
2. XELR8 Holdings to Announce 2007 Third Quarter Results on Wednesday, October 31, 2007
3. NightHawk Radiology Holdings, Inc. Announces Appointment of David Engert to the Board of Directors
4. InfuSystem Holdings Appoints Two New Board Members
5. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Second Quarter Earnings Webcast
6. Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings
7. Zimmer Holdings, Inc. Reports First Quarter Financial Results
8. NightHawk Radiology Holdings, Inc. to Host Conference Call to Discuss First Quarter 2008 Earnings Results
9. Lincare Holdings Inc. Announces First Quarter 2008 Financial Results
10. Zimmer Holdings to Present at Morgan Stanley Healthcare Unplugged Conference
11. HMS Holdings Corp. Hosts First Quarter 2008 Financial Teleconference and Presentation
Post Your Comments:
(Date:4/21/2017)... CITY, Utah (PRWEB) , ... April 21, 2017 ... ... of wilderness therapy treatment for adolescents and young adults, has kicked off its ... 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy for Mental ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Patient Advocacy ... Health System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition ... advocates. DeVaro was honored with the award at The Beryl Institute’s annual Patient ...
(Date:4/21/2017)... ... ... Alive for Wellness is a group of clinical professionals and ... Alive team uses advanced behavioral sciences treatment modalities to accomplish their goals. ... struggle is based on 10 modalities of treatment that include: , ...
(Date:4/21/2017)... Ramon, CA (PRWEB) , ... April 21, 2017 , ... ... might not understand the estate planning process, or where to even begin. “Now more ... unresolved if you are to properly protect yourself and your family,” said attorney Lisa ...
(Date:4/21/2017)... ... , ... During April 21-23, Super-Sod will join the vendor market of the ... everyone — from the avid gardener to the landscape admirer — during the three-day ... in a grand venue, and we are certainly looking forward to participating in this ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical Center ... in Nashville , Tennesse have been ... Sphincter Stimulation for GERD (LESS GERD) trial. The EndoStim ... long-term reflux control by restoring normal function to the ... million people in the United States ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
Breaking Medicine Technology: